CONTEXT: Multiple autoimmune disorders (e.g. Addison's disease, type 1 diabetes, celiac disease) are associated with HLA-DR3, but it is likely that alleles of additional genes in linkage disequilibrium with HLA-DRB1 contribute to disease. OBJECTIVE: The objective of the study was to characterize major histocompatability complex (MHC) haplotypes conferring extreme risk for autoimmune Addison's disease (AD). DESIGN, SETTING, AND PARTICIPANTS: Eighty-six 21-hydroxylase autoantibody-positive, nonautoimmune polyendocrine syndrome type 1, Caucasian individuals collected from 1992 to 2009 with clinical AD from 68 families (12 multiplex and 56 simplex) were genotyped for HLA-DRB1, HLA-DQB1, MICA, HLA-B, and HLA-A as well as high density MHC single-nucleotide polymorphism (SNP) analysis for 34. MAIN OUTCOME MEASURES: AD and genotype were measured. RESULT: Ninety-seven percent of the multiplex individuals had both HLA-DR3 and HLA-B8 vs. 60% of simplex AD patients (P = 9.72 × 10(-4)) and 13% of general population controls (P = 3.00 × 10(-19)). The genotype DR3/DR4 with B8 was present in 85% of AD multiplex patients, 24% of simplex patients, and 1.5% of control individuals (P = 4.92 × 10(-191)). The DR3-B8 haplotype of AD patients had HLA-A1 less often (47%) than controls (81%, P = 7.00 × 10(-5)) and type 1 diabetes patients (73%, P = 1.93 × 10(-3)). Analysis of 1228 SNPs across the MHC for individuals with AD revealed a shorter conserved haplotype (3.8) with the loss of the extended conserved 3.8.1 haplotype approximately halfway between HLA-B and HLA-A. CONCLUSION: Extreme risk for AD, especially in multiplex families, is associated with haplotypic DR3 variants, in particular a portion (3.8) but not all of the conserved 3.8.1 haplotype.
CONTEXT: Multiple autoimmune disorders (e.g. Addison's disease, type 1 diabetes, celiac disease) are associated with HLA-DR3, but it is likely that alleles of additional genes in linkage disequilibrium with HLA-DRB1 contribute to disease. OBJECTIVE: The objective of the study was to characterize major histocompatability complex (MHC) haplotypes conferring extreme risk for autoimmune Addison's disease (AD). DESIGN, SETTING, AND PARTICIPANTS: Eighty-six 21-hydroxylase autoantibody-positive, nonautoimmune polyendocrine syndrome type 1, Caucasian individuals collected from 1992 to 2009 with clinical AD from 68 families (12 multiplex and 56 simplex) were genotyped for HLA-DRB1, HLA-DQB1, MICA, HLA-B, and HLA-A as well as high density MHC single-nucleotide polymorphism (SNP) analysis for 34. MAIN OUTCOME MEASURES: AD and genotype were measured. RESULT: Ninety-seven percent of the multiplex individuals had both HLA-DR3 and HLA-B8 vs. 60% of simplex ADpatients (P = 9.72 × 10(-4)) and 13% of general population controls (P = 3.00 × 10(-19)). The genotype DR3/DR4 with B8 was present in 85% of AD multiplex patients, 24% of simplex patients, and 1.5% of control individuals (P = 4.92 × 10(-191)). The DR3-B8 haplotype of ADpatients had HLA-A1 less often (47%) than controls (81%, P = 7.00 × 10(-5)) and type 1 diabetespatients (73%, P = 1.93 × 10(-3)). Analysis of 1228 SNPs across the MHC for individuals with AD revealed a shorter conserved haplotype (3.8) with the loss of the extended conserved 3.8.1 haplotype approximately halfway between HLA-B and HLA-A. CONCLUSION: Extreme risk for AD, especially in multiplex families, is associated with haplotypic DR3 variants, in particular a portion (3.8) but not all of the conserved 3.8.1 haplotype.
Authors: Theresa A Aly; Elise Eller; Akane Ide; Katherine Gowan; Sunanda R Babu; Henry A Erlich; Marian J Rewers; George S Eisenbarth; Pamela R Fain Journal: Diabetes Date: 2006-05 Impact factor: 9.461
Authors: Akane Ide; Sunanda R Babu; David T Robles; Tianbao Wang; Henry A Erlich; Teodorica L Bugawan; Marian Rewers; Pamela R Fain; George S Eisenbarth Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317
Authors: W Huang; E Connor; T D Rosa; A Muir; D Schatz; J Silverstein; S Crockett; J X She; N K Maclaren Journal: J Clin Endocrinol Metab Date: 1996-07 Impact factor: 5.958
Authors: G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi Journal: J Clin Endocrinol Metab Date: 1999-10 Impact factor: 5.958
Authors: G Gambelunghe; R Gerli; E Bartoloni Bocci; P Del Sindaco; M Ghaderi; C B Sanjeevi; O Bistoni; V Bini; A Falorni Journal: Rheumatology (Oxford) Date: 2004-11-02 Impact factor: 7.580
Authors: M Rewers; T L Bugawan; J M Norris; A Blair; B Beaty; M Hoffman; R S McDuffie; R F Hamman; G Klingensmith; G S Eisenbarth; H A Erlich Journal: Diabetologia Date: 1996-07 Impact factor: 10.122
Authors: L Yu; K W Brewer; S Gates; A Wu; T Wang; S R Babu; P A Gottlieb; B M Freed; J Noble; H A Erlich; M J Rewers; G S Eisenbarth Journal: J Clin Endocrinol Metab Date: 1999-01 Impact factor: 5.958
Authors: Peter Baker; Pam Fain; Heinrich Kahles; Liping Yu; John Hutton; Janet Wenzlau; Marian Rewers; Klaus Badenhoop; George Eisenbarth Journal: J Clin Endocrinol Metab Date: 2012-06-20 Impact factor: 5.958
Authors: Peter R Baker; Priyaanka Nanduri; Peter A Gottlieb; Liping Yu; Georgeanna J Klingensmith; George S Eisenbarth; Jennifer M Barker Journal: Clin Endocrinol (Oxf) Date: 2012-05 Impact factor: 3.478
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Priyaanka Nanduri; Taylor M Triolo; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2011-05-11 Impact factor: 5.958
Authors: Simon H S Pearce; Anna L Mitchell; Stuart Bennett; Phil King; Sukesh Chandran; Sath Nag; Shu Chen; Bernard Rees Smith; John D Isaacs; Bijay Vaidya Journal: J Clin Endocrinol Metab Date: 2012-07-05 Impact factor: 5.958
Authors: Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy Journal: J Clin Endocrinol Metab Date: 2016-01-13 Impact factor: 5.958
Authors: Alexander Hellesen; Sigrid Aslaksen; Lars Breivik; Ellen Christine Røyrvik; Øyvind Bruserud; Kine Edvardsen; Karl Albert Brokstad; Anette Susanne Bøe Wolff; Eystein Sverre Husebye; Eirik Bratland Journal: Front Immunol Date: 2021-10-14 Impact factor: 7.561